Characteristics, Management and In-Hospital Clinical Outcomes Among Inpatients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in China: Results from the Phase I Data of ACURE Study.

The study aimed to give a comprehensive overview of characteristics and evaluate in-hospital clinical outcomes among hospitalized acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients in China using data from the AECOPD inpatient registry (ACURE). The ACURE is an ongoing, national, multicenter, observational registry. Participants enrolled during phase I stage (1 A total of 5334 AECOPD inpatients from 163 sites in 28 provinces or province-level municipalities were included. Among all participants, 78.8% were males and the median age was 69.0 [interquartile range (IQR): 63.0-76.0] years. The proportions of current and former smokers were 23.6% and 44.2%, respectively. The median age at COPD diagnosis was 64.0 (IQR: 57.0-71.0) years and 88.7% participants demonstrated at least one comorbidity. During stable period, only 56.9% subjects received pharmacological therapies and the influenza vaccination rate was 2.9%. During hospitalization, 99.5% subjects received pharmacological treatments and antibiotics were prescribed to 90.9% participants. The all-cause in-hospital mortality was 0.1% and no significant difference was found across hospital categories. Clinical features of Chinese AECOPD inpatients were different from those of other populations. In real-world China, the clinical management during stable period was unsatisfied, whereas therapy during hospitalization was effective regarding in-hospital clinical outcomes regardless of hospital category.

Informations de copyright

© 2021 Liang et al.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest in this work. The ACURE study is funded by the Chinese Academy of Medical Sciences, basic scientific research business fee fund of central level public welfare scientific research institutes-Research on Prevention and Control System of Chronic Airway Diseases (grant number 2019TX320005), National Key R&D Program of China (grant number 2016YFC1303900, 2016YFC1304300), CAMS Innovation Fund for Medical Sciences (CIFMS) (grant number 2018-I2M-1-001). The funders of the study had no role in study design, data collection and management, data analysis, data interpretation, writing of the manuscript, and the decision to submit the manuscript for publication.